Chas­ing 'Holy Grail' STAT3 tar­get, Hous­ton start­up re­fu­els with $74M to ze­ro in on liv­er can­cer

Tvar­di launched out of Hous­ton with the promise of fi­nal­ly de­vel­op­ing the right in­hibitors for the Holy Grail tar­get of STAT3 — un­der the guid­ance of se­r­i­al en­tre­pre­neur Ron De­Pin­ho and his col­league David Tweardy, a lead­ing ex­pert in the field. Al­most three years lat­er, they say they have the proof of con­cept da­ta to keep go­ing.

It’s good enough for a $74 mil­lion Se­ries B, a big jump from the $9 mil­lion they got in the last round and, CEO Im­ran Al­ib­hai would add, a re­flec­tion of the rep his team has built.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.